製品番号: HY-18649A

Galidesivir

(別名: BCX4430; Immucillin-A)

12 Cited Publications

カスタマーレビュー

Based on 12 publication(s) in Google Scholar

Galidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC₅₀s ranging from ~3 to ~68 μM.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.89%
CAS 番号: 249503-25-1
分子式: C₁₁H₁₅N₅O₃
分子量:265.27

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Galidesivir 構造式

CAS 番号: 249503-25-1

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (12)
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

RNA Polymerase

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示 :

Filovirus アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
Caco-2	CC₅₀	82.8 μM Compound: Galidesivir	Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition by neutral red cytopathic assay Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition by neutral red cytopathic assay	[PMID: 36965227]
Calu-3	CC₅₀	>50 μM Compound: Galidesivir	Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition by neutral red cytopathic assay Cytotoxicity against human Calu-3 cells assessed as cell growth inhibition by neutral red cytopathic assay	[PMID: 36965227]
Huh-7	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against human Huh-7 cells infected with DENV-2 assessed as reduction in cell viability by neutral red dye based assay Cytotoxicity against human Huh-7 cells infected with DENV-2 assessed as reduction in cell viability by neutral red dye based assay	[PMID: 37077387]
Huh-7	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against human Huh-7 cells infected with DENV-2 assessed as reduction in cell viability by visual analysis Cytotoxicity against human Huh-7 cells infected with DENV-2 assessed as reduction in cell viability by visual analysis	[PMID: 37077387]
Huh-7	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against human Huh-7 cells infected with Yellow fever virus assessed as reduction in cell viability by neutral red dye based assay Cytotoxicity against human Huh-7 cells infected with Yellow fever virus assessed as reduction in cell viability by neutral red dye based assay	[PMID: 37077387]
Huh-7	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against human Huh-7 cells infected with Yellow fever virus assessed as reduction in cell viability by visual assay Cytotoxicity against human Huh-7 cells infected with Yellow fever virus assessed as reduction in cell viability by visual assay	[PMID: 37077387]
Huh-7	CC₅₀	>89 μM Compound: 8; BCX4430	Cytotoxicity against human HuH7 cells Cytotoxicity against human HuH7 cells	[PMID: 31549836]
MDCK	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against dog MDCK cells infected with Influenza A virus H1N1 assessed as reduction in cell viability by neutral red dye based assay Cytotoxicity against dog MDCK cells infected with Influenza A virus H1N1 assessed as reduction in cell viability by neutral red dye based assay	[PMID: 37077387]
MDCK	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against dog MDCK cells infected with Influenza A virus H1N1 assessed as reduction in cell viability by visual analysis Cytotoxicity against dog MDCK cells infected with Influenza A virus H1N1 assessed as reduction in cell viability by visual analysis	[PMID: 37077387]
RD	CC₅₀	>89 μM Compound: 8; BCX4430	Cytotoxicity against human RD cells Cytotoxicity against human RD cells	[PMID: 31549836]
RD	EC₅₀	3.8 μg/mL Compound: 8; BCX4430	Inhibition of RNA-dependent RNA polymerase in Zika virus PRVABC-59 infected in human RD cells assessed as antiviral activity by neutral dye based colorimetric method Inhibition of RNA-dependent RNA polymerase in Zika virus PRVABC-59 infected in human RD cells assessed as antiviral activity by neutral dye based colorimetric method	[PMID: 31549836]
RD	EC₅₀	3.8 μg/mL Compound: 8; BCX4430	Inhibition of RNA-dependent RNA polymerase in Zika virus Ugandan MR-766 infected in human RD cells assessed as antiviral activity by neutral dye based colorimetric method Inhibition of RNA-dependent RNA polymerase in Zika virus Ugandan MR-766 infected in human RD cells assessed as antiviral activity by neutral dye based colorimetric method	[PMID: 31549836]
Vero	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against African green monkey Vero cells infected with DENV-2 assessed as reduction in cell viability by neutral red dye based assay Cytotoxicity against African green monkey Vero cells infected with DENV-2 assessed as reduction in cell viability by neutral red dye based assay	[PMID: 37077387]
Vero	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against African green monkey Vero cells infected with DENV-2 assessed as reduction in cell viability by visual assay Cytotoxicity against African green monkey Vero cells infected with DENV-2 assessed as reduction in cell viability by visual assay	[PMID: 37077387]
Vero	CC₅₀	>89 μM Compound: 8; BCX4430	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 31549836]
Vero	EC₅₀	3.8 μg/mL Compound: 8; BCX4430	Inhibition of RNA-dependent RNA polymerase in Zika virus Malaysian P 6-740 infected in African green monkey Vero cells assessed as antiviral activity by neutral dye based colorimetric method Inhibition of RNA-dependent RNA polymerase in Zika virus Malaysian P 6-740 infected in African green monkey Vero cells assessed as antiviral activity by neutral dye based colorimetric method	[PMID: 31549836]
Vero	EC₅₀	3.8 μg/mL Compound: 8; BCX4430	Inhibition of RNA-dependent RNA polymerase in Zika virus PRVABC-59 infected in African green monkey Vero cells assessed as antiviral activity by neutral dye based colorimetric method Inhibition of RNA-dependent RNA polymerase in Zika virus PRVABC-59 infected in African green monkey Vero cells assessed as antiviral activity by neutral dye based colorimetric method	[PMID: 31549836]
Vero	EC₅₀	3.8 μg/mL Compound: 8; BCX4430	Inhibition of RNA-dependent RNA polymerase in Zika virus Ugandan MR-766 infected in African green monkey Vero cells assessed as antiviral activity by neutral dye based colorimetric method Inhibition of RNA-dependent RNA polymerase in Zika virus Ugandan MR-766 infected in African green monkey Vero cells assessed as antiviral activity by neutral dye based colorimetric method	[PMID: 31549836]
Vero 76	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against African green monkey Vero 76 cells infected with MERS-CoV assessed as reduction in cell viability by neutral red dye based analysis Cytotoxicity against African green monkey Vero 76 cells infected with MERS-CoV assessed as reduction in cell viability by neutral red dye based analysis	[PMID: 37077387]
Vero 76	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against African green monkey Vero 76 cells infected with MERS-CoV assessed as reduction in cell viability by visual analysis Cytotoxicity against African green monkey Vero 76 cells infected with MERS-CoV assessed as reduction in cell viability by visual analysis	[PMID: 37077387]
Vero 76	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against African green monkey Vero 76 cells infected with Rift valley fever virus assessed as reduction in cell viability by neutral red dye based analysis Cytotoxicity against African green monkey Vero 76 cells infected with Rift valley fever virus assessed as reduction in cell viability by neutral red dye based analysis	[PMID: 37077387]
Vero 76	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against African green monkey Vero 76 cells infected with Rift valley fever virus assessed as reduction in cell viability by visual analysis Cytotoxicity against African green monkey Vero 76 cells infected with Rift valley fever virus assessed as reduction in cell viability by visual analysis	[PMID: 37077387]
Vero 76	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against African green monkey Vero 76 cells infected with Zika virus assessed as reduction in cell viability by neutral red dye based assay Cytotoxicity against African green monkey Vero 76 cells infected with Zika virus assessed as reduction in cell viability by neutral red dye based assay	[PMID: 37077387]
Vero 76	CC₅₀	>100 μM Compound: Galidesivir	Cytotoxicity against African green monkey Vero 76 cells infected with Zika virus assessed as reduction in cell viability by visual analysis Cytotoxicity against African green monkey Vero 76 cells infected with Zika virus assessed as reduction in cell viability by visual analysis	[PMID: 37077387]
Vero 76	CC₅₀	>295.7 μM Compound: Galidesivir	Cytotoxicity against african green monkey Vero 76 cells assessed as cell growth inhibition by neutral red cytopathic assay Cytotoxicity against african green monkey Vero 76 cells assessed as cell growth inhibition by neutral red cytopathic assay	[PMID: 36965227]

体外実験

Cellular kinases phosphorylate Galidesivir (BCX4430) to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination^[1].
Galidesivir effectively inhibits the infection of Vero cells with YFV. The EC50 determined by the neutral red uptake assay is 8.3 μg/ml (24.5 μM)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Galidesivir (BCX4430) is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections. In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, Galidesivir has demonstrated pronounced efficacy^[1].
Galidesivir (4 mg/kg; i.p.; twice daily for 7 days) is effectively in a hamster model of yellow fever (YF)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Syrian golden hamsters (hamsters infected with YF virus)^[4]
Dosage:

4 mg/kg of body weight
Administration:

I.p.; twice daily for 7 days
Result:

Significantly improved the survival of hamsters infected with YFV.

化学情報

CAS 番号 249503-25-1
性状 Solid
分子量 265.27
分子式 C₁₁H₁₅N₅O₃
Color White to off-white
SMILES

O[C@H]1[C@H](C2=CNC3=C2N=CN=C3N)N[C@H](CO)[C@H]1O
別名

BCX4430; Immucillin-A
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (12)

All

Sort by:

Journal Impact Factor

Nucleic Acids Res

COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]

2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390
Microorganisms

Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors. [Abstract]

2021 Mar 31;9(4):734. PMID: 33807492
Antiviral Res

Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses. [Abstract]

2017 Jun:142:63-67. PMID: 28336346
Antimicrob Agents Chemother

Viral RNA-Dependent RNA Polymerase Inhibitor 7-Deaza-2'- C-Methyladenosine Prevents Death in a Mouse Model of West Nile Virus Infection. [Abstract]

2019 Feb 26;63(3):e02093-18. PMID: 30642926
Viruses

Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]

2020 Jun 10;12(6):628. PMID: 32532085
Virology

BCX4430 inhibits the replication of rabies virus by suppressing mTOR-dependent autophagy invitro. [Abstract]

2023 Aug:585:21-31. PMID: 37267717
Exp Ther Med

Separation of cordycepin from Cordyceps militaris fermentation supernatant using preparative HPLC and evaluation of its antibacterial activity as an NAD+-dependent DNA ligase inhibitor. [Abstract]

2016 Sep;12(3):1812-1816. PMID: 27588098
J AOAC Int

Green and Versatile High Throughput Microwell Oxidation-Based Spectrophotometric Methods for Determination of Galidesivir in Capsules. [Abstract]

2024 Jun 13:qsae047. PMID: 38870529
bioRxiv

2025 Sep 22.
Biomed Pharmacother

Drug repositioning: Identification of potent inhibitors of NS3 protease and NS5 RdRp for control of DENV infection. [Abstract]

2025 Apr 28:187:118104. PMID: 40300391
bioRxiv

2025 April 22.
bioRxiv

2025 January 29.

溶剤 & 溶解度

体外:

H₂O : 100 mg/mL (376.97 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7697 mL

18.8487 mL

37.6974 mL

5 mM

0.7539 mL

3.7697 mL

7.5395 mL

10 mM

0.3770 mL

1.8849 mL

3.7697 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Taylor R, et al. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J Infect Public Health. 2016;9(3):220-226. [Content Brief]

[2]. Elfiky AA, et al. ICN-1229, Remdesivir, PSI-7977, Galidesivir, and GS 1278 against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 2020 Mar 25:117592. [Content Brief]

[3]. Warren TK, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508(7496):402-405. [Content Brief]

[4]. Julander JG, et al. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob Agents Chemother. 2014;58(11):6607-6614. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	3.7697 mL	18.8487 mL	37.6974 mL	94.2436 mL
	5 mM	0.7539 mL	3.7697 mL	7.5395 mL	18.8487 mL
	10 mM	0.3770 mL	1.8849 mL	3.7697 mL	9.4244 mL
	15 mM	0.2513 mL	1.2566 mL	2.5132 mL	6.2829 mL
	20 mM	0.1885 mL	0.9424 mL	1.8849 mL	4.7122 mL
	25 mM	0.1508 mL	0.7539 mL	1.5079 mL	3.7697 mL
	30 mM	0.1257 mL	0.6283 mL	1.2566 mL	3.1415 mL
	40 mM	0.0942 mL	0.4712 mL	0.9424 mL	2.3561 mL
	50 mM	0.0754 mL	0.3770 mL	0.7539 mL	1.8849 mL
	60 mM	0.0628 mL	0.3141 mL	0.6283 mL	1.5707 mL
	80 mM	0.0471 mL	0.2356 mL	0.4712 mL	1.1780 mL
	100 mM	0.0377 mL	0.1885 mL	0.3770 mL	0.9424 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Galidesivir

12 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Galidesivir

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Protein-protein Interaction Inhibitor Library

Heterocyclic Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Galidesivir

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示

Filovirus アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (12)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Galidesivir

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Protein-protein Interaction Inhibitor Library

Heterocyclic Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Galidesivir

DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示

Filovirus アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (12)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Galidesivir 関連分類

HY-18649A 関連分類